Interactive Panel Discussion
"The Future Of Biotech:
Managing Clinical Trials In The Internet Economy"
TUESDAY, JUNE 18, 2002
Dr. C. Budd Colby, Principal, Colby Biomedical Consultants
Andreatta, Chief Financial Officer and Chief Operating Officer,
Mr. Thomas Tremblay, Director of Clinical Operations, POINT Biomedical
Dr. Naomi Fried, General Manager and Vice President for Business
Development, 1747, Inc. (http://1747.net)
here to view the Summary for this Interactive Panel Discussion.
Acrobat Reader is needed to view the documents above).
Registration and Networking: 5:00 - 6:00 p.m.
Panel: 6:00 - 8:00 p.m.
Open to the Public. $20 fee. No fee to Center Sponsors.
Pre-registration highly recommended due to limited seating.
The rapid pace of new drug development, the plethora
of biotech companies in need of getting drugs to the market, and
the advent of the Internet and Web are having a strong impact on
the structuring and management of clinical trials -- the expensive
and time-consuming process of testing medical drugs that occur in
three overlapping phases which last several years each. The right
strategic business decisions and compliance with the U.S. Food and
Drug Administration's Center for Drug Evaluation and Research (CDER)
are key to the success of clinical trials, inevitably getting new
drugs to the U.S. market.
At this Panel, come hear experts in the biotech industry put their
stake on the ground on the following questions:
Will the processing and management of clinical trials be 'Web-ified'?
If so, in what time horizon?
What mediating technology and non-technology factors are needed
for clinical trials to incorporate Internet- and Web-based solutions?
What challenges are biotech companies facing in structuring and
managing clinical trials? For instance, in the areas of patient
acquisition and case management; data acquisition, storage, retrieval,
and mining; and data analysis?
What solutions, including Internet- and Web-based ones, exist to
meet these challenges?
What critical technology solutions are still needed?
Come hear about these developments during the first half of this
two-hour Panel. During the second hour, audience participants will
have the opportunity to engage in a lively, interactive discussion
with the panelists.
ABOUT THE PANELISTS
ABOUT BUDD COLBY
C. Budd Colby is Principal at Colby Biomedical Consultants,
an international private consulting practice providing services
to diverse members of the biotechnology industry community. Dr.
Colby has 12 years of academic research experience in the areas
of biochemistry, genetics, virology, and cell biology with emphasis
on their application to cancer and infectious diseases.
Beginning in 1967, Dr. Colby held research and teaching positions
at a number of prestigious academic institutions and carried out
research in the areas of cancer and infectious diseases. In 1979,
Dr. Colby initiated and managed the recombinant interferon program
at Cetus Corporation where he established and coordinated international
research and business. In 1983, he joined Triton Biosciences, Inc.
as the Founding Scientist and Senior Director of Technology Development.
From 1992-1995, he served as Vice President, Research & Development
at Metabolex, Inc., a biotechnology company focused on diabetes.
Between 1998-2001, he held the positions of Vice President, Business
Development and Chief Operating Officer of Neugenesis Corporation.
At Sloan Kettering Institute, Dr. Colby was Research Associate and
Founding Member of the International Laboratories for the Molecular
Biology of Interferon Systems. Dr. Colby earned his B.S. in Chemistry
at Memphis State University and his Ph.D. in Biochemistry at the
University of Kentucky.
Andreatta is Chief Financial Officer & Chief Operating Officer
at HopeLink Corporation (http://www.hopelink.com).
He brings over 17 years of experience in growth management and planning
for complex financial, technical accounting, and regulatory environments
in both private and public companies. Mr. Andreatta was most recently
a Partner in KPMG's technology practice in the San Francisco Bay
Area where he specialized in software, media, and service companies,
including many successful startups. He oversaw numerous IPOs and
transaction work; supported companies in the development of their
business plans, systems, policies, and complex transactions; and
led consulting and international assignments. In 1995, he took leadership
of KPMG's Internet and Start-Up Practices in San Francisco. Mr.
Andreatta was a member of KPMG's National E-Commerce Strategy Leadership
Team and Silicon Valley Marketing Council and headed the company's
New Media Practice on the West Coast. He is a graduate of Santa
Clara University with a B.S. in Business.
ABOUT NAOMI FRIED
Naomi Fried is General Manager and Vice President for
Business Development at 1747, Inc. (http://1747.net)
Dr. Fried has over 12 years of experience in engineering and healthcare.
During the past four years, she has assisted eHealth start-ups in
fundraising, developing business strategies and strategic partnerships,
and creating Web-based revenue models. Former clients have included
medical content Web sites, vertical health portals, alternative
health networks, and risk and disease management providers. Dr.
Fried advised Stanfords School of Medicine in the creation
and spin-out of its medical informatics Internet start-up e-SKOLAR
(formerly SHINE), as well as served as Interim President during
its first year. Dr. Fried earned a B.S. in Chemistry from the University
of California at Berkeley (summa cum laude) and a Ph.D. in Materials
Science Engineering from MIT.
Nandini Tandon is Partner in the Life Sciences team at RBC Capital
the venture capital arm of RBC Financial Group. She joined
the team in early 2002, opening their San Francisco offices. Dr.Tandon
has extensive experience in business development with Chiron Corporation,
Hyseq, Inc., and Zyomyx, Inc. She has also worked at Bay BioTech
Link, a consulting firm, as well as Glaxo, Inc., the UK-headquartered
pharmaceutical company. Dr. Tandon holds a Ph.D. in biochemistry
from Duke University and a B.S. in chemistry from Hollins College.
ABOUT THOMAS TREMBLAY
Thomas Tremblay is Director of Clinical Operations
at POINT Biomedical Corporation (http://www.pointbio.com),
responsible for implementing the clinical development plan for CARDIOsphere,
an ultrasound contrast agent being developed for the diagnosis of
coronary artery disease and myocardial perfusion defects. Mr. Tremblay
is a registered nurse and has worked in various clinical settings
from outpatient clinics to intensive care units. For the past 12
years, Mr. Tremblay has worked in clinical research beginning as
a Study Coordinator at the University of California in San Francisco
and, more recently, as a Clinical Research Associate and Project
Manager at Genentech; Clinical Operations Manager at Titan Pharmaceuticals;
and Assistant Director of Clinical Operations at IntraBiotics Pharmaceuticals,
REGISTRATION AND FURTHER INFORMATION
Registration is not necessary, but highly recommended
due to limited seating. To register, send your name, title, company
name, telephone number, and email address to:
Ms. Claire Kahrobaie
Manager, Client Services
Silicon Valley World Internet Center